BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29619216)

  • 1. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.
    Viswanath P; Radoul M; Izquierdo-Garcia JL; Luchman HA; Gregory Cairncross J; Pieper RO; Phillips JJ; Ronen SM
    Cancer Metab; 2018; 6():3. PubMed ID: 29619216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.
    Viswanath P; Radoul M; Izquierdo-Garcia JL; Ong WQ; Luchman HA; Cairncross JG; Huang B; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2018 May; 78(9):2290-2304. PubMed ID: 29358170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
    Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
    Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
    Batsios G; Viswanath P; Subramani E; Najac C; Gillespie AM; Santos RD; Molloy AR; Pieper RO; Ronen SM
    Sci Rep; 2019 Jul; 9(1):10521. PubMed ID: 31324855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy.
    Shen X; Voets NL; Larkin SJ; de Pennington N; Plaha P; Stacey R; McCullagh JSO; Schofield CJ; Clare S; Jezzard P; Cadoux-Hudson T; Ansorge O; Emir UE
    Metabolites; 2019 Feb; 9(2):. PubMed ID: 30791611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
    Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
    Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.
    Javier R; Wang W; Drumm M; McCortney K; Sarkaria JN; Horbinski C
    PLoS One; 2022; 17(2):e0257725. PubMed ID: 35134075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
    Drumm MR; Wang W; Sears TK; Bell-Burdett K; Javier R; Cotton KY; Webb B; Byrne K; Unruh D; Thirunavu V; Walshon J; Steffens A; McCortney K; Lukas RV; Phillips JJ; Mohamed E; Finan JD; Santana-Santos L; Heimberger AB; Franz CK; Kurz J; Templer JW; Swanson GT; Horbinski C
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37104042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
    Leu S; von Felten S; Frank S; Boulay JL; Mariani L
    J Neurooncol; 2016 Apr; 127(2):363-72. PubMed ID: 26780338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.
    Bader JM; Deigendesch N; Misch M; Mann M; Koch A; Meissner F
    Cell Rep Med; 2023 Jan; 4(1):100877. PubMed ID: 36584682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
    Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
    Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
    Braun Y; Filipski K; Bernatz S; Baumgarten P; Roller B; Zinke J; Zeiner PS; Ilina E; Senft C; Ronellenfitsch MW; Plate KH; Bähr O; Hattingen E; Steinbach JP; Mittelbronn M; Harter PN
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):379-393. PubMed ID: 33080075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
    Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
    PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
    Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
    Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.